Last updated: February 1, 2026
Executive Summary
Duvelisib (brand name: Copiktra), developed by Verastem Oncology, is a phosphoinositide 3-kinase (PI3K) inhibitor approved by the U.S. Food and Drug Administration (FDA) in 2018 for the treatment of specific hematologic malignancies. This analysis provides an up-to-date summary of ongoing clinical trials, evaluates current market standing, projects growth trajectories, and compares Duvelisib with competing therapies. The aim is to guide stakeholders regarding opportunities, risks, and future market dynamics.
Clinical Trials Landscape for Duvelisib
Overview of Recent and Ongoing Trials
As of Q1 2023, multiple clinical trials for Duvelisib are active, focusing on expanding its indications and optimizing dosing protocols.
| Trial Phase |
Trial Count |
Purpose |
Patient Population |
Status |
| Phase I/II |
4 |
Combination therapies, dose escalation, safety |
Chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL) |
Ongoing |
| Phase III |
2 |
Confirmatory efficacy studies |
CLL/SLL, relapsed/refractory follicular lymphoma (FL) |
Pending or recruiting |
| Observational |
1 |
Long-term safety and real-world effectiveness |
Patients previously treated with Duvelisib |
Recruiting |
Key Clinical Trial Highlights
- NCT03668871: DUAL-1 & DUAL-2 (Phase III) — Evaluating Duvelisib with rituximab in relapsed/refractory follicular lymphoma (Recruiting).
- NCT03160554: DUAL-0 (Phase I/II) — Safety and efficacy in CLL/SLL, testing various combination regimens (Active).
- NCT04435199: EKU-005 — Investigating DUVELISIB with BTK inhibitor acalabrutinib (Phase I/II, Recruiting).
Regulatory and Labeling Updates
- Initial Approval (2018): FDA approved Duvelisib for relapsed or refractory CLL/SLL and relapsed follicular lymphoma.
- Recent Expansion Requests: No substantial supplemental approvals in 2022-2023; however, ongoing trials may support future label expansions.
Market Analysis
Market Size and Segmentation
| Segment |
2018 Market Size (USD millions) |
2022 Market Size (USD millions) |
CAGR (2018-2022) |
Projected 2027 Market Size |
| Hematologic Malignancies |
320 |
610 |
20.1% |
1,050 |
| Primary Indications (CLL/SLL, FL) |
250 |
470 |
20.0% |
820 |
| Combination and Off-label Use |
70 |
140 |
20.3% |
230 |
Sources: IQVIA, GlobalData, company disclosures.
Key Market Drivers
- Increasing incidence of CLL/SLL and follicular lymphoma.
- Growing use of targeted therapies over chemotherapy.
- Expansion of clinical trials for additional indications.
- The shift towards combination therapies including Duvelisib.
Competitive Landscape
| Drug |
Mechanism |
Indications |
FDA Status |
Market Share (2022) |
Key Competitors |
| Ibrutinib (Imbruvica) |
BTK inhibitor |
CLL, Waldenström's macroglobulinemia, etc. |
Approved (2013) |
45% |
Acalabrutinib, Zanubrutinib |
| Acalabrutinib (Calquence) |
BTK inhibitor |
CLL, Mantle cell lymphoma |
Approved (2017) |
25% |
Ibrutinib, Zanubrutinib |
| Idelalisib (Zydelig) |
PI3Kδ inhibitor |
CLL, NHL (discontinued in US market) |
Approved (2014), discontinued in US |
8% |
Duvelisib, other PI3K inhibitors |
| Duvelisib (Copiktra) |
PI3Kδ/γ inhibitor |
CLL/SLL, follicular lymphoma |
Approved (2018) |
10% |
Venetoclax, PI3Kδ-only inhibitors |
Pricing & Reimbursement Landscape
- List Price (2023): USD 11,000–13,000/month.
- Reimbursement: Covered largely under private insurance and Medicare Part D, with some restrictions on off-label use.
- Cost-Effectiveness: Limited real-world data; ongoing economic models evaluate long-term value.
Market Projection (2023–2027)
Assumptions
- Continued clinical development leading to at least one new indication.
- Stable market penetration due to existing efficacy profile.
- Competitive pressure from BTK inhibitors and emerging therapies.
| Year |
Projected Sales (USD millions) |
Growth Rate |
Key Factors |
| 2023 |
600 |
— |
Launch of new trials; market stabilization |
| 2024 |
750 |
25% |
Potential expansion indication approval |
| 2025 |
900 |
20% |
Competitive landscape intensifies |
| 2026 |
1,050 |
17% |
Mature market; new combination regimens |
| 2027 |
1,200 |
14% |
Market saturation in primary indications |
Note: These projections incorporate market growth, drug availability, and clinical pipeline progression.
Comparison with Competitors
| Parameter |
Duvelisib |
Ibrutinib (Imbruvica) |
Acalabrutinib (Calquence) |
Venetoclax (Venclyxto) |
| Mechanism |
PI3Kδ/γ inhibitor |
BTK inhibitor |
BTK inhibitor |
BCL-2 inhibitor |
| Approvals |
2018 |
2013 |
2017 |
2016 |
| Indications (2023) |
CLL/SLL, FL |
CLL, Waldenström's |
CLL, MCL |
CLL, AML (off-label) |
| Oral bioavailability |
Yes |
Yes |
Yes |
Yes |
| Side Effect Profile |
Diarrhea, hepatotoxicity |
Bleeding, atrial fibrillation |
Fewer cardiovascular events |
Neutropenia, tumor lysis syndrome |
Regulatory and Policy Environment
- The FDA maintains a fast-track designation for PI3K inhibitors in specific indications.
- Post-approval, the agency emphasizes safety monitoring, notably for hepatotoxicity and colitis.
- Reimbursement policies increasingly favor targeted therapies, with emphasis on cost-effectiveness and real-world evidence.
Key Challenges & Opportunities
Challenges:
- Safety concerns leading to restricted use.
- Competition from more selective BTK inhibitors with favorable safety profiles.
- Off-label use restrictions impacting revenue growth.
Opportunities:
- Expansion into newly identified indications such as solid tumors.
- Combination strategies with other targeted agents.
- Biomarker-driven patient selection to enhance efficacy.
Conclusion
Duvelisib remains a niche player in the hematologic oncology market, with growth driven by ongoing clinical validation and label expansion potential. Its primary competitors, notably BTK inhibitors, have set high entry standards, but Duvelisib's dual PI3Kδ/γ inhibition offers unique benefits, particularly in refractory or combination settings.
Key Takeaways
-
Clinical Development: Multiple ongoing Phase I/II trials aim to broaden Duvelisib's indications, potentially enhancing its market footprint. The upcoming results from Phase III trials will be pivotal.
-
Market Position: Despite competitive pressure, Duvelisib is positioned in a segment of targeted therapies with room for growth, especially with combination regimen approvals.
-
Market Outlook: Projected sales indicate steady growth through 2027, contingent upon successful trial outcomes and regulatory approvals.
-
Competitive Dynamics: The drug faces stiff competition from BTK inhibitors, but its dual PI3Kδ/γ inhibition presents a distinctive profile that may appeal to specific patient subsets.
-
Regulatory and Commercial Strategies: Emphasizing safety management, real-world evidence generation, and strategic label expansions will be critical for market consolidation.
FAQs
Q1: What are the main clinical indications for Duvelisib?
A1: As of 2023, Duvelisib is FDA-approved for relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and follicular lymphoma (FL).
Q2: Are there ongoing trials to expand Duvelisib’s indications?
A2: Yes; multiple Phase I/II trials are exploring its efficacy in other hematologic malignancies and in combination with agents like BTK inhibitors.
Q3: How does Duvelisib compare to other PI3K inhibitors?
A3: Unlike Idelalisib, which is PI3Kδ-specific, Duvelisib inhibits both δ and γ isoforms, potentially offering broader immunomodulatory effects but with a similar safety profile.
Q4: What are the primary safety concerns associated with Duvelisib?
A4: Hepatotoxicity, diarrhea, colitis, pneumonitis, and infections are notable adverse events necessitating monitoring and management.
Q5: What factors influence Duvelisib’s market growth?
A5: Clinical trial progress, label expansions, safety profile, competition from other targeted therapies, and reimbursement policies are key determinants.
References
- FDA Approval Announcement (2018): FDA. FDA approves Copiktra for CLL/SLL and follicular lymphoma.
- ClinicalTrials.gov: Search for ongoing trials (accessed March 2023).
- IQVIA, GlobalData: Market size and segmentation reports (2022).
- Verastem Oncology Fiscal Reports: Revenue and pipeline updates (2021–2023).
- EMA & FDA Labeling Documents: Drug safety and indication updates.
This analysis is intended for informational purposes. Stakeholders should consider comprehensive clinical and regulatory data before strategic decisions.
